Following the diagnosis of MODY3, the insulin therapy was replaced with Gliclazide (60 mg, twice daily), resulting in optimal glycemic control (HbA1c = 6.7%). The gene discussed is INS; the disease is maturity-onset diabetes of the young type 3.